This single-center, randomized study aims to compare the intraoperative detection rates of axillary lymph nodes marked with carbon suspension versus metallic markers in breast cancer patients (T1-3N1M0) before neoadjuvant therapy. Primary endpoint: frequency of marked lymph node identification during surgery. Secondary endpoints: time from marking to surgery and quality of life (EORTC QLQ-BR23).
Women ≥18 years.
Morphologically confirmed breast cancer (T1-3N1M0).
ECOG 0-1.
Indication for neoadjuvant therapy.
No lymph node regression post-neoadjuvant therapy (persistent N1).
Distant metastasis progression.
Severe comorbidities (NYHA III-IV, COPD GOLD D, Child-Pugh C).